Tarlatamab's Flexible Dosing Shows Promise in Relapsed Small Cell Lung Cancer

Introduction

New findings from the Phase 2 DeLLphi-309 study, presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC), are offering a potential paradigm shift in the treatment of relapsed small cell lung cancer (SCLC). The study investigated whether tarlatamab, a bispecific T-cell engager, could maintain its efficacy and safety profile when administered at less frequent intervals than the established every-two-week schedule. The results suggest that extended dosing regimens—specifically 20 mg every three weeks and 30 mg every four weeks—may provide comparable clinical benefits with enhanced patient convenience.

Key Details

Study Design: The randomized Phase 2 DeLLphi-309 study enrolled 252 patients with SCLC whose disease had progressed or recurred after first-line platinum-based chemotherapy. Participants were randomized to receive intravenous tarlatamab at 10 mg every two weeks, 20 mg every three weeks, or 30 mg every four weeks, following an initial 1 mg step dose.
Efficacy Outcomes: As of May 7, 2026, the blinded independent central review (BICR) confirmed objective response rates (ORR) of 40% for the every-two-week regimen, 31% for the every-three-week regimen, and 27% for the every-four-week regimen. Investigator-assessed ORRs were 36%, 37%, and 31%, respectively. Median progression-free survival (PFS) by BICR was 4.2 months, 4.1 months, and 2.7 months for the respective dosing schedules.
Overall Survival: Six-month overall survival (OS) rates were notably high across all arms: 72% for the every-two-week schedule, 85% for the every-three-week schedule, and 69% for the every-four-week schedule. Median OS had not yet been reached at approximately nine months of median follow-up.
Safety Profile: Treatment-emergent adverse events were generally consistent across all regimens. Cytokine release syndrome (CRS) occurred in 60% to 70% of patients, predominantly grade 1 or 2. Immune effector cell-associated neurotoxicity syndrome (ICANS) was observed in 6% to 12% of patients. No new or unexpected safety signals were identified.
Pharmacokinetics: Steady-state trough concentrations of tarlatamab were comparable across the three dosing schedules, indicating consistent drug exposure regardless of administration frequency.

Background

Tarlatamab has previously shown significant promise in SCLC. A standard regimen of 10 mg administered every two weeks has demonstrated superior overall survival compared to chemotherapy in patients with previously treated SCLC. This established efficacy made the DeLLphi-309 study a critical next step to explore if treatment could be optimized for patient convenience without compromising clinical outcomes. Small cell lung cancer is an aggressive form of lung cancer with limited treatment options, particularly after initial therapy fails. Therefore, innovations that enhance treatment flexibility and maintain efficacy are highly sought after.

Impact Analysis

The results from DeLLphi-309 are significant because they suggest that the benefits of tarlatamab can be achieved with less frequent dosing. The every-three-week regimen, in particular, showed a notable increase in the six-month OS rate (85%) compared to the every-two-week schedule (72%). While ORR and PFS were numerically lower with extended dosing, the differences were not substantial enough to dismiss these regimens, especially when considering the potential for improved patient adherence and quality of life. The comparable safety profiles further bolster the case for flexible dosing, as patients are unlikely to face increased toxicity.

“These data suggest that the tarlatamab 20 mg every-three-week and 30 mg every-four-week regimens may offer treatment flexibility for patients with SCLC and that alternative dosing schedules for bispecific T-cell engagers may achieve outcomes consistent with an established regimen.”

Broader Context

Bispecific T-cell engagers represent a rapidly evolving class of immunotherapies. Tarlatamab targets DLL3, a protein highly expressed in SCLC but with limited expression in normal tissues, making it an attractive therapeutic target. The development of flexible dosing schedules for such novel agents is crucial for their widespread adoption and long-term patient management. As the field moves towards more personalized and patient-centric care, offering options that reduce the burden of treatment administration is paramount. This aligns with a broader trend in oncology to balance efficacy with patient experience and accessibility.

Future Outlook

The positive results from the DeLLphi-309 study pave the way for potential regulatory submissions seeking approval for these extended-interval dosing regimens of tarlatamab. Further analysis, including longer-term follow-up data, will be essential to fully understand the durability of response and the long-term safety profile of these schedules. Real-world data will also play a crucial role in confirming these findings and guiding clinical practice. The success of flexible dosing in tarlatamab could also influence the development of other bispecific antibodies, encouraging similar investigations into optimized administration schedules.

Conclusion

The Phase 2 DeLLphi-309 study provides compelling evidence that tarlatamab can be administered effectively at extended intervals—every three or four weeks—in patients with relapsed SCLC. These flexible dosing options appear to maintain comparable efficacy and safety to the standard every-two-week regimen, offering significant advantages in terms of patient convenience and potentially treatment adherence. This development represents a meaningful step forward in optimizing the management of SCLC and underscores the potential of bispecific T-cell engagers in lung cancer therapy.